Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | RGS4 | P49798 | 1/20 | 0.31 |
| ▸ | RGS8 | P57771 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | CTSG | P08311 | 1/20 | 0.30 |
| ▸ | CTRC | Q99895 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8082411 | 0.76 | ADRA2C (0.33) | ADRA2CTP53GAAKMT2A | |
| SCHEMBL11878881 | 0.74 | — | — | |
| SCHEMBL19923764 | 0.71 | ADRA2C (0.30) | ADRA2C | |
| SCHEMBL818514 | 0.70 | — | — | |
| SCHEMBL31293584 | 0.67 | — | — | |
| SCHEMBL17360666 | 0.67 | CAPN1 (0.41) | CAPN1KDM4E | |
| SCHEMBL21846679 | 0.65 | PIK3CD (0.33) | — | |
| SCHEMBL12616358 | 0.65 | — | — | |
| SCHEMBL16519377 | 0.65 | ALDH1A1 (0.35) | ADRA2CTP53GAAKMT2AKDM4E | |
| SCHEMBL13495745 | 0.63 | CAPN1 (0.34) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242491-A1 | DIMERS FROM BIOREACHABLE MOLECULES AS COPOLYMERS | ZYMERGEN INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20230242720-A1 | MODULUS MODIFIERS AND FILMS THEREOF | ZYMERGEN ACQUISITION SUB, INC. | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242491-A1 | DIMERS FROM BIOREACHABLE MOLECULES AS COPOLYMERS | HDHD5, HAO2, ALAD | CAPN1 3978/4885ADRA2C 4440/4885TP53 324/4885 |
| US-20230242720-A1 | MODULUS MODIFIERS AND FILMS THEREOF | SHBG, PTMS, SERPINA6 | CAPN1 3810/4885ADRA2C 3646/4885TP53 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.